Inhibitory effects of c9, t11-conjugated linoleic acid on invasion of human gastric carcinoma cell line SGC-7901

Bing-Qing Chen, Yan-Mei Yang, Yan-Hui Gao, Jia-Ren Liu, Ying-Ben Xue, Xuan-Lin Wang, Yu-Mei Zheng, Jing-Shu Zhang, Rui-Hai Liu

INFORMATION:

Conjugated linoleic acid (CLA) refers to a class of positional and geometrical isomers of linoleic acid (18:2) with conjugated double bonds. The conjugated double bonds are mainly located at sites 9 and 11 or 10 and 12, and each double bond may be in the cis or trans configuration[1-5]. CLA exists in dairy products and meat of ruminants, the former is the principal source of CLA, of which c9, t11-CLA is the major isomer and represents 85-90 % of total CLA in bovine milk[6]. CLA is mainly produced from linoleic acid by rumen bacteria during biohydrogenation[6], although CLA can also be synthesized in non-ruminants by Δ9-desaturase from trans-11 18:1, another intermediate in rumen biohydrogenation[7]. The level of CLA in human adipose tissue has been reported to be associated with the consumption of dairy fat[8]. Besides, CLA can be synthesized in the laboratory and commercially synthesized CLA is available as a dietary supplement and has been shown to be non-toxic[9].

CLA is a potent cancer preventive agent and has chemoprotective properties[10-20]. In animal models of chemical carcinogenesis, CLA has been shown to inhibit skin papillomas[10,11], forestomach neoplasia[12,13] and mammary tumors[14-20]. Several studies[21-28] suggest that CLA is cytostatic and cytotoxic to a variety of human cancer cells, including hepatoma, malignant melanoma, colorectal cancer, breast carcinomas, and gastric cancer cells. Moreover, CLA also plays a role in reducing the tumor size and inhibiting the metastasis of transplanted human breast cancer cells and prostate cancer cells in SCID mice[29,30].

Gastric cancer is one of the most common malignancies in China[11-34] and its metastasis is the major cause of death in cancer patients. Our previous studies have revealed that c9, t11-CLA is an effective agent to prevent gastric cancer[35,36], and could inhibit the invasion of mouse melanoma[37]. However, it is unclear whether c9, t11-CLA influences on the metastasis of gastric cancer. Thus, we investigated the effect of c9-t11-CLA on the metastasis of human gastric carcinoma cell line SGC-7901.

MATERIALS AND METHODS

Materials

c9,t11-CLA with 98 % purity, was obtained from Dr. Rui-Hai Liu (Food Science and Toxicology, Department of Food Science, Cornell University, Ithaca, NY, USA). It was dissolved in ethanol and then diluted to the following concentrations: 25 µmol/L, 50 µmol/L, 100 µmol/L and 200 µmol/L, respectively.

Methods

Cell culture Human gastric adenocarcinoma cells (SGC-7901) purchased from Cancer Research Institute of Beijing (China) were cultured at 37 °C in PRMI 1640 (Gibco Co.) medium supplemented with fetal calf serum (100 ml/L), penicillin (100×10^3 U/L), streptomycin (100 mg/L) and L-glutamine (2 mmol/L). The pH was maintained at 7.2-7.4 by...
equilibration with 5 % CO₂. The SGC-7901 cells were sub-cultured with EDTA.

**In vitro invasion assay** Invasion assay assessing the ability of cells to invade a synthetic basement membrane was performed in transwell chambers (Costar Co. USA) with a polycarbonate filter of 8.0 µm pore size, separating the upper and lower chambers. The top surface of the polycarbonate filter was coated with Matrigel, the bottom with fibronectin. SGC-7901 cells (2×10⁴) treated with different concentrations of c₉, t₁₁-CLA (25, 50, 100, and 200 µmol/L) for 24 h were added to the upper transwell chamber in 100 µl of serum-free RPMI 1640 medium containing 0.1 % bovine serum albumin (BSA, Gibco Co.) and 600 µl of serum-free BSA-RPMI 1640 medium was added to the lower chamber. After 4 h, the filters were fixed in methanol and stained with hematoxylin and eosin (HE). The noninvading cells on the surface of the filter membrane were removed with a cotton swab. Cells on the bottom surface of the filter were counted and the cell means were obtained from five high-power fields under a light microscope. The inhibitory rate (IR) was calculated as follows:

\[
\text{IR(%) = } \frac{\text{Number of cells in negative control group} - \text{Number of invasive cells in test groups}}{\text{Number of invasive cells in negative control group}} \times 100
\]

**Chemotaxied-motion assay** The assay also was performed in transwell chambers (Costar Co. USA) with a polycarbonate filter of 8.0 µm pore size separating the upper and lower chambers. The bottom surface of filter was coated with fibronectin. The lower chambers were filled with 600 µl of serum-free BSA-RPMI 1640 medium. SGC-7901 cells (2×10⁴) treated with different concentrations of c₉, t₁₁-CLA (25, 50, 100, and 200 µmol·L⁻¹) for 24 h were added to the upper chambers, the chambers then were treated the same as invasion assay. SGC-7901 cells that migrated from the upper chamber to the bottom of filter were counted and the means of cell numbers from five high-power fields under a light microscope were calculated. The inhibitory rate (IR) was calculated as follows:

\[
\text{IR(%) = } \frac{\text{Number of cells in negative control group} - \text{Number of invasive cells in test groups}}{\text{Number of invasive cells in negative control group}} \times 100
\]

**Cell adhesion assay** 96-well plates (Nunc. Co.) were incubated at 37 °C with laminin or fibronectin or Matrigel for 1 h and then blocked with phosphate-buffered saline (PBS) containing 10 g/L BSA for another 1 h at the same temperature. The SGC-7901 cells exposed to different concentrations of c₉, t₁₁-CLA (25, 50, 100, and 200 µmol·L⁻¹) for 3-4 h under nondenaturing conditions. After electrophoresis, the gels were incubated in 2.5 % Triton X-100 for 1 h and then incubated in substrate buffer [50 µmol/L Tris (pH 7.5), 10 mmol/L CaCl₂, 200 mmol/L NaCl and 1 µmol/L ZnCl₂] for 12-16 h at 37 °C. After incubation, the gels were stained in a solution containing 1 g/L Coomasie blue R250 for 4 h, and destained with 45 % methanol and 10 % acetic acid until clear bands were shown.

**RT-PCR** SGC-7901 cells were treated at different concentrations of c₉, t₁₁-CLA (25, 50, 100, and 200 µmol/L) for 24 h and collected by centrifugation. Total RNA was isolated using Trizol reagent according to the manufacturer’s instructions. The concentrations and purity of total RNA were determined by DUR 640 nucleic acid and protein analyzer (Beckman, USA). The first-strand cDNA was synthesized from 5 µg of total RNA using 50 pmol of oligo (dT) primers, 10 units of AMV reverse transcriptase XL (TAKAKA Biotechnology, Dalian Co.), 20 units RNase Inhibitor, 5×buffer and 10 mmol/L each dNTP in a total volume of 20 µL. PCRs were performed using respectively primers for TIMP-1, TIMP-2 and β-actin. The primer sequences are described in Table 1. PCR was carried out in 25 µl volume containing 4 µl of cDNA template, 10×PCR buffer, 20 µmol/L each primer, 2.5 mmol/L dNTP mixture, 2.5 unit of Taq Polymerase. After denaturation at 94 °C for 5 min, the reaction mixtures were subjected to 35 cycles of PCR amplification in PCT-100™ programmable thermal controller (MJ Research Inc., USA). Each cycle consisted of 1 min of denaturation at 94 °C, a primer specific annealing temperature and period (at 58 °C for 45 s for TIMP-1 and 58 °C for 30 s for TIMP-2, at 55 °C for 30 s for β-actin) and extension at 72 °C (1.5 min for TIMP-1, 1 min for TIMP-2, 45 s for β-actin).

### Table 1 Primer sequence and size of expected PCR products

| Primer | Sequence | Lenth (bp) |
|--------|----------|------------|
| β-actin sense | 5'-AAGGATCCCTAATGTGGGC-3' | 532 |
| antisense | 5'-CATCTCTTGTGCTGAAAGTC-3' | 106 |
| TIMP-1 sense | 5'-CTGTTGGCTGTGAGAAGTCAAGCAG-3' | 490 |
| antisense | 5'-TTTACAGCCCTGAGAGGCTGTC-3' | 106 |
| TIMP-2 sense | 5'-AGACCTAATGATCGGCGCCA-3' | 490 |
| antisense | 5'-GTACCACCGCCGGAAGACCT-3' | 490 |

The amplified products were separated in 20 g·L⁻¹ agarose gel and stained with ethidium bromide. After electrophoresis, the gel was observed and photographed under ultraviolet reflector. The density and area of each band were analyzed using ChemiImager™ 4000 digital system (Alpha Innotech Corporation, USA).

**Statistical analysis** Analysis of data was performed using the Student’s t test. A value of P<0.05 was considered as statistically significant.

**RESULTS**

**Effect of c₉,t₁₁-CLA on invasion in SGC-7901 cells** As shown in Table 2, the invasive abilities of SGC-7901 cells treated with 50 µmol/L, 100 µmol/L, and 200 µmol/L of c₉, t₁₁-CLA were significantly lower than those of the negative control group (P<0.01), and the inhibitory rates were 53.7 %, 40.9 % and 29.3 %, respectively. At 25 µmol/L c₉,t₁₁-CLA, the invasive ability of SGC-7901 cells did not differ from that of the negative control group (P>0.05). The effect of c₉,
$t_{11}$-CLA on the invasive ability of SGC-7901 cells is shown in Figure 1.

### Table 2 Effect of $c_{9},t_{11}$-CLA on invasive ability of SGC-7901 cells

| Groups          | Invasive cell number ($\bar{x} \pm s$) | Inhibitory frequency(%) |
|-----------------|---------------------------------------|-------------------------|
| 200 $\mu$mol/L | 23.2±2.9 $a$                           | 53.7                    |
| 100 $\mu$mol/L | 29.6±3.3 $a$                           | 40.9                    |
| 50 $\mu$mol/L  | 35.4±2.8 $a$                           | 29.3                    |
| 25 $\mu$mol/L  | 44.9±3.1                               | 10.4                    |
| Negative control| 50.1±4.6                               | 0                      |

$\bar{x}$ <0.01, compared with the negative control group.

### Effect of $c_{9},t_{11}$-CLA on Chemotaxic migration ability in SGC-7901 cells

The chemotaxic ability of SGC-7901 cells at 200 $\mu$mol/L $c_{9},t_{11}$-CLA was lower than that of the negative control group ($P<0.05$) and the inhibitory rate was 16.0%. At 100 $\mu$mol/L, 50 $\mu$mol/L and 25 $\mu$mol/L of $c_{9},t_{11}$-CLA, the chemotaxic ability of SGC-7901 cells did not differ from that of the negative control group ($P>0.05$). The effect of $c_{9},t_{11}$-CLA on the chemotaxic migration ability of SGC-7901 cells is shown in Figure 2.

### Table 3 Effect of $c_{9},t_{11}$-CLA on migration ability of SGC-7901 cells

| Groups          | Cell number ($\bar{x} \pm s$) | Inhibitory frequency(%) |
|-----------------|-------------------------------|-------------------------|
| 200 $\mu$mol/L | 50.8±3 $a$                    | 16.0                    |
| 100 $\mu$mol/L | 52.5±3.1                     | 13.2                    |
| 50 $\mu$mol/L  | 54.4±3.9                     | 10.1                    |
| 25 $\mu$mol/L  | 55.0±4.4                     | 10.1                    |
| Negative control| 60.5±4.2                     | 0                      |

$\bar{x}$ <0.05, compared with the negative control group.

### Effect of $c_{9},t_{11}$-CLA on attachment ability in SGC-7901 cells

As shown in Figure 3, at levels of 25 $\mu$mol/L, 50 $\mu$mol/L, 100 $\mu$mol/L and 200 $\mu$mol/L $c_{9},t_{11}$-CLA could decrease the attachment to FN, LN or Matrigel ability of SGC-7901 cells and the inhibitory effect was positively correlated with the concentration of $c_{9},t_{11}$-CLA.

### Effect of $c_{9},t_{11}$-CLA on collagenase ability in SGC-7901 cells

As shown in Figure 4 and Figure 5, at levels of 200 $\mu$mol/L, 100 $\mu$mol/L and 50 $\mu$mol/L $c_{9},t_{11}$-CLA significantly reduced 92 kDa type IV collagenase (MMP-9) activity in the serum-free medium supernatant of SGC-7901 cells, but at 25 $\mu$mol/L $c_{9},t_{11}$-CLA, the collagenase ability did not differ from that in the negative control group. $c_{9},t_{11}$-CLA did not influence on the 72 kDa collagenase (MMP2) activity.

### Effect of $c_{9},t_{11}$-CLA on expression of TIMP-1 and TIMP-2 mRNA in SGC-7901 cells

The expression of TIMP-1 and TIMP-2 mRNA of SGC-7901 cells treated at different concentrations of $c_{9},t_{11}$-CLA increased in comparison with that of the negative control group. As the
concentrations of 9,11-CLA increased, the expression of TIMP-land TIMP-2 mRNA was upregulated. Moreover, the increase of TIMP-2 mRNA expression was more obvious (Figure 6,7).

**DISCUSSION**

Metastasis is a multistage process involving interactions between tumor cells and extracellular matrix (ECM). Metastasis of cancer cells required several sequent steps, including changes in cell-ECM interaction, disconnection of intercellular adhesions, separation of single cell from tumor tissue, degradation of ECM, migration of tumor cells into the ECM, invasion of lymph and blood vessels, immunologic escape in the circulatory system, adhesion to endothelial cells, extravasation from lymph and blood vessels, proliferation of cells and induction of angiogenesis[39]. The complex metastasis cascade could be described as cell attachment to the extracellular matrix, proteolytic dissolution of the matrix, invasion, attachment, proteolytic dissolution of the matrix and movement are required for tumor cell through Matrigel and polycarbonate, thus the reconstituted basement membrane invasion assay could better reflects the invasion ability of tumor. This study showed that the invasion ability of SGC-7901 cells treated with 200 µmol/L, 100 µmol/L and 50 µmol/L of 9, 11-CLA was significantly inhibited, which was consistent with the study result from mice melanoma[37]. We conclude that CLA can inhibit the invasion and metastasis of mice melanoma and human gastric adenocarcinoma.

Many studies indicated the importance of cancer cell-matrix interaction. Cell and matrix interactions promoted cell migration, proliferation, and ECM degradation[39-43]. Also, it has been shown that prevention of tumor cell adhesion and migration was related to the inhibition of tumor cell invasion into the basement membrane, and agents inhibiting cell attachment in vitro decreased the invasion and metastatic potential of tumor cells in vivo. Therefore, cellular interactions with ECM, which promote adhesion and migration, were thought to be required for tumor invasion, migration, and metastasis. We demonstrated that after incubated with 200 µmol/L, 100 µmol/L and 50 µmol/L of 9,11-CLA for 1 h, the attachment to extracellular matrix component of SGC-7901 cells was significantly reduced, which was consistent with our previous finding[44], indicating CLA could inhibit the attachment to extracellular matrix component of tumor cells. However, in previous study we found that CLA could not affect the direct migration of B16-MB cells and in this study we observed that 200 µmol/L CLA could reduce the direct migration of SGC-7901 cells. Therefore, attachment of tumor cells to matrix inhibited by 9,11-CLA may be a mechanism for the inhibition of invasion and needs further study.

Basement membrane is a barrier for tumor invasion and metastasis. Tumor cell invasion through the ECM was an essential process in cancer metastasis[42]. Matrix metalloproteinases (MMPs) were important enzymes for the proteolysis of extracellular matrix proteins such as collagen, laminin and fibronectin[44]. Most MMPs were synthesized and secreted from the cells as proenzymes[45]. Human MMP-2 (gelatinase A/72kD type IV collagenase) and MMP-9 (gelatinase B/92kD type IV collagenase) were thought to be the key enzymes for degrading IV collagen, which is a principal structural protein of the basement membrane[46]. Studies revealed that increased production of MMPs was correlated with the invasion, metastasis, and angiogenesis of tumors[47]. In this study, we found that 9,11-CLA significantly reduced 92 kDa type (MMP9) activities in the serum-free medium supernatant of SGC-7901 cells, but had no effect on 72 kDa collagenase (MMP2), showing that CLA could inhibit the key enzymes for degrading IV collagen. Therefore, it is conceivable that tumor cells could degrade basement membrane via reduction of type IV collagenase activities. MMPs activity is regulated by tissue inhibitors of metalloproteinase (TIMPs).

**Figure 4** Effects of 9,11-CLA on Gelatinase secretion in SGC-7901 cells detected by zymography. A, B, C, D are 200 µmol/L, 100 µmol/L, 50 µmol/L, 25 µmol/L c9t11-CLA, respectively. E is the negative control group.

**Figure 5** Quantitation of 92 and 72 kDa type IV Collagenase levels in SGC-7901 cells by ChemiImager 4000. A, B, C, D are 200 µmol/L, 100 µmol/L, 50 µmol/L, 25 µmol/L c9t11-CLA, respectively. E is the negative control group.

**Figure 6** Effects of 9,11-CLA on expression of TIMP-1 mRNA and TIMP-2 mRNA in SGC-7901 cells detected by RT-PCR. Top: Expression of TIMP-1 mRNA. Middle: Expression of TIMP-2 mRNA. A, B, C, D are 200 µmol/L, 100 µmol/L, 50 µmol/L, 25 µmol/L c9t11-CLA, respectively. E is the negative control group.

**Figure 7** Quantitation of TIMP-1 and TIMP-2 mRNA levels in the SGC-7901 cells by ChemiImager 4000. A, B, C, D are 200 µmol/L, 100 µmol/L, 50 µmol/L, 25 µmol/L c9t11-CLA, respectively. E is the negative control group.
There have been four members of the TIMP family determined up to date, of which TIMP-1 and TIMP-2 were best characterized as inhibitors of all known MMPs[41]. We found that TIMP-1 and TIMP-2 mRNA expression increased in SGC-7901 cells treated with c9,11-CLA, indicating that c9,11-CLA may inhibit the MMPs activity via inducing the expression of TIMP-1 and TIMP-2 mRNA and then inhibit the metastasis of SGC-7901 cells.

In conclusion, c9,11-CLA inhibits several essential steps of metastasis in SGC-7901 cells. It can inhibit cell-matrix component interaction, reduce the activity of MMPs and increase the expression of TIMP1 and TIMP2 mRNA. Its mechanism in SGC-7901 cells metastasis needs to be studied further.

ACKNOWLEDGEMENTS

We are grateful to Dr. Rui-Hai Liu from Cornell University for providing 98% purity of c9,11-CLA.

REFERENCES

1. Sebedio JL, Gnaedig S, Chardigny JM. Recent advances in conjugated linoleic acid research. Curr Opin Clin Nutr Metab Care 1999; 2: 499-506
2. Pariza MW, Park Y, Cook ME. Mechanisms of action of conjugated linoleic acid: evidence and speculation. Proc Soc Exp Biol Med 2000; 223: 8-13
3. Pariza MW, Park Y, Cook ME. Conjugated linoleic acid and the control of cancer and obesity. Toxicol Sci 1999; 52(Suppl 2): 107-110
4. Whigham LD, Cook ME, Atkinson RL. Conjugated linoleic acid: implications for human health. Pharmacol Res 2000; 42: 503-510
5. Macnald H B. Conjugated linoleic acid and disease prevention: a review of current knowledge. J Am Coll Nutr 2000; 19(Suppl 2): 1115-1185
6. Kim YJ, Liu RH, Bond DR, Russell JB. Effect of linoleic acid concentration on conjugated linoleic acid production by Buthyrivibrio fibrisolvens A38. Appl Environ Microbiol 2000; 66: 5226-5230
7. Santora JE, Palmquist DL, Roehrig KL. Trans-vaccenic acid in human gastric cancer grafted onto nude mice. Cancer Lett 1997; 111-1185
8. Belury MA, Nickel KP, Bird CE, Wu Y. Dietary conjugated linoleic acid is desaturated to conjugated linoleic acid in mice. J Nutr 2000; 130: 208-215
9. Jiang J, Wolk A, Vessby B. Relation between the intake of milk fat and the occurrence of conjugated linoleic acid in human adipose tissue. Am J Clin Nutr 1999; 70: 21-27
10. Scimeca JA. Toxicological evaluation of dietary conjugated linoleic acid in male Fischer 344 rats. Food Chem Toxicol 1998; 36: 391-395
11. Belury MA, Nickel KP, Bird CE, Wu Y. Dietary conjugated linoleic acid modulation of phorbol ester skin tumor promotion. Nutr Cancer 1996; 26: 149-157
12. Pariza MW. Hargraves WA. A beef-derived mutagenesis modulator inhibits initiation of mouse epidermal tumors by 7,12-dimethylbenz(a)anthracene. Carcinogenesis 1989; 6: 591-593
13. Ha YL, Storkson J, Pariza MW. Inhibition of benzo(a)pyrene-induced mouse forestomach neoplasia by conjugated dienoic derivatives of linoleic acid. Cancer Res 1990; 50: 1097-1101
14. Zhu Y, Qiu J, Chen B, Liu RH. The inhibitory effect of conjugated linoleic acid on mice forestomach neoplasia induced by benzo(a)pyrene. Zhonghua Yufang Yixue Zazhi 2001; 35: 19-22
15. Ip C, Jiang C, Thompson HJ, Scimeca JA. Retention of conjugated linoleic acid in the mammary gland is associated with tumor inhibition during the post-initiation phase of carcinogenesis. Carcinogenesis 1997; 18: 755-759
16. Ip C, Singh M, Thompson HJ, Scimeca JA. Conjugated linoleic acid suppresses mammary carcinogenesis and proliferative activity of the mammary gland in the rat. Cancer Res 1994; 54: 1212-1215
17. Ip C, Banni S, Angioni E, Carta G, McGinley J, Thompson HJ, Barbano D, Bauman D. Conjugated linoleic acid–enriched butter fat alters mammary gland morphology and reduces cancer risk in rats. J Nutr 1999; 129: 2135-2142
18. Thompson H, Zhu Z, Banni S, Darcy K, Loftus T, Ip C. Morphological and biochemical status of the mammary gland as influenced by conjugated linoleic acid: implication for a reduction in mammary cancer risk. Cancer Res 1997; 57: 5067-5072
19. Banni S, Angioni E, Casu V, Melis MP, Carta G, Corongiu FP, Thompson H, Ip C. Decrease in linoleic acid metabolites as a potential mechanism in cancer risk reduction by conjugated linoleic acid. Carcinogenesis 1999; 20: 1019-1024
20. Kimoto N, Hirose M, Futakuchi M, Iwata T, Kasai M, Shirai T,Site-dependent modulating effects of conjugated fatty acids from safflower oil in a rat two-stage carcinogenesis model in female Sprague-Dawley rats. Cancer Lett 2001; 168: 15-21
21. Ip C, Ip MM, Loftus T, Shoemaker S, Shea-Eaton W. Induction of apoptosis by conjugated linoleic acid in cultured mammary tumor cells and premalignant lesions of the rat mammary gland. Cancer Epidemiol Biomarkers Prec 2000; 9: 689-696
22. Shultz TD, Chew BP, Seaman WR, Lueddeke LO. Inhibitory effect of conjugated dienoic derivatives of linoleic acid and beta-carotene on the in vitro growth of human cancer cells. Cancer Lett 1992; 63: 125-133
23. Igarashi M, Miyazawa T. Newly recognized cytotoxic effect of conjugated trienoic fatty acids on human tumor cells. Cancer Lett 2000; 148: 173-179
24. Igarashi M, Miyazawa T. The growth inhibitory effect of conjugated linoleic acid on a human hepatoma cell line, HepG2, is induced by a change in fatty acid metabolism, but not the facilitation of lipid peroxidation in the cells. Biochim Biophys Acta 2003; 1530: 162-171
25. Park Y, Allen KG, Shultz TD. Modulation of MCF-7 breast cancer cell signal transduction by linoleic acid and conjugated linoleic acid in culture. Anticancer Res 2000; 20: 669-676
26. O'Shea M, Devrey R, Lawless F, Murphy J, Stanton C. Milk fat conjugated linoleic acid (CLA) inhibits growth of human mammary MCF-7 cancer cells. Anticancer Res 2000; 20: 3591-3601
27. O'Shea M, Stanton C, Devrey R. Antioxidant enzyme defence responses of human MCF-7 and SW480 cancer cells to conjugated linoleic acid. Anticancer Res 1999; 19: 1953-1959
28. Cunningham DC, Harrison LY, Shultz TD. Proliferative responses of normal human mammary mammary and MCF-7 breast cancer cells to linoleic acid, conjugated linoleic acid and eicosanoid synthesis inhibitors in culture. Anticancer Res 1997; 17: 197-203
29. Schonberg S, Krocak HE. The inhibitory effect of conjugated dienoic derivatives (CLA) of linoleic acid on the growth of human tumor cell lines is in part due to increased lipid peroxidation. Anticancer Res 1995; 15: 1241-1246
30. Visonneau S, Cesano A, Tepper SA, Scimeca JA, Santoli D, Kritchovsky D. Conjugated linoleic acid suppresses the growth of human breast adenocarcinoma cells in SCID mice. Anticancer Res 1997; 17: 969-973
31. Cesano A, Visonneau S, Scimeca JA, Kritchovsky D, Santoli D. Opposite effects of linoleic acid and conjugated linoleic acid on human prostate cancer in SCID mice. Anticancer Res 1998; 18: 1429-1434
32. Liu LX, Liu ZH, Jiang HC, Qu X, Zhang WH, Wu LF, Zhu AL, Wang XQ, Wu M. Profiling of differentially expressed genes in human Gastric carcinoma by cDNA expression array. World J Gastroenterol 2002; 8: 580-585
33. Song ZJ, Gong P, Wu YE. Relationship between the expression of iNOS,VEGF, tumor angiogenesis and gastric cancer. World J Gastroenterol 2002; 8: 591-595
34. Shi XY, Zhao FZ, Dai X, Ma LS, Dong XY, Fang J. Effect of jiangjiaziweijing capsule on gastric precancerous lesions in rats. World J Gastroenterol 2002; 8: 608-612
35. Zhao AG, Zhao HL, Jin XJ, Yang JK, Tang LD. Effects of Chinese Jianpi herbs on cell apoptosis and related gene expression in human gastric carcinoma by cDNA expression array. World J Gastroenterol 2002; 8: 792-796
36. Liu J, Chen B, Liu R, Lu G. Inhibitory effect of conjugated linoleic acid on human gastric carcinoma cell line. We sheng Yan jiu 2001; 28: 353-357
37. Liu JR, Li BX, Chen BQ, Han XH, Xue YB, Yang YM, Zheng YM, Liu RH. Effect of cis-9(trans)-11-conjugated linoleic acid on cell cycle of gastric adenocarcinoma cell line(SGC-7901). World J Gastroenterol 2002; 8: 224-229
38. Xue Y, Chen B, Zheng Y, Yuan L. Effects of conjugated linoleic acid on the metastasis of mouse melanoma B16-MB. W e sheng Yan jiu 2001; 30: 37-39
38 Ries C, Loher F, Zang C, Ismair MG, Petrides PE. Matrix metalloproteinase production by bone marrow mononuclear cells from normal individuals and patients with acute and chronic myeloid leukemia or myelodysplastic syndromes. Clin Cancer Res 1999; 5: 1115-1124

39 Yoon SO, Kim MM, Chung AS. Inhibitory effect of selenite on invasion of HT1080 tumor cells. J Biol Chem 2001; 276: 20085-20092

40 Ara T, Deyama Y, Yoshimura Y, Higashino F, Shindoh M, Matsumoto A, Fukuda H. Membrane type 1-matrix metalloproteinase expression is regulated by E-cadherin through the suppression of mitogen-activated protein kinase cascade. Cancer Lett 2000; 157: 115-121

41 Seftor RE, Seftor EA, Gehlsen KR, Stetler-Stevenson WG, Brown PD, Ruoslahti E, Hendrix MJ. Role of the alpha v beta 3 integrin in human melanoma cell invasion. Proc Natl Acad Sci U S A 1992; 89: 1557-1561

42 Nakahara H, Nomizu M, Akiyama SK, Yamada Y, Yeh Y, Chen WT. A mechanism for regulation of melanoma invasion. Ligand of alpha6beta1 integrin by laminin G peptides. J Biol Chem 1996; 271: 27221-27224

43 Giancotti FG, Ruoslahti E. Integrin signaling. Science 1999; 285: 1028-1032

44 Kim MH, Kitson RP, Albertsson U, Nannmark U, Basse PH, Kuppen PJ, Hokland ME, Goldfarb RH. Secreted and membrane-associated matrix metalloproteinases of IL-2-activated NK cells and their inhibitors. J Immunol 2000; 164: 5883-5889

45 Nagase H, Woessner Jr. Matrix metalloproteinases. J Biol Chem 1999; 274: 21491-21494

46 Andela VB, Schwarz EM, Puzas JE, O’Keefe RJ, Rosier RN. Tumor metastasis and the reciprocal regulation of prometastatic and antimetastatic factors by nuclear factor kappaB. Cancer Res 2000; 60: 6557-6562

47 Westermarck J, Kahari VM. Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J 1999; 13: 781-792

Edited by Ren SY and Wang XL